UPDATE: Edwards Lifesciences Raises FY2026 Adj EPS Guidance from $2.95-$3.05 to $2.97-$3.05 vs $3.00 Est; Narrows FY2026 Sales Guidance from $6.600B-$6.900B to $6.766B vs $6.767B Est
Benzinga Newsdesk 2 weeks ago
NewsGuidanceHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Edwards Lifesciences (NYSE:EW) raises FY2026 Adj EPS guidance from $2.95-$3.05 to $2.97-$3.05 vs $3.00 analyst estimate. Narrows FY2026 sales outlook from $6.600 billion-$6.900 billion to $6.766 billion vs $6.767
Edwards Lifesciences (NYSE:EW) raises FY2026 Adj EPS guidance from $2.95-$3.05 to $2.97-$3.05 vs $3.00 analyst estimate. Narrows FY2026 sales outlook from $6.600 billion-$6.900 billion to $6.766 billion vs $6.767 billion estimate.
